Previously we showed that MRP-1/CD9 might prevent tumor metastasis by suppression of cell motility and invasion of tissue barriers. The present study explored the possibility of preventing metastasis of mouse melanoma BL6 by expression of MRP-1/CD9 through gene transfer. A replication-de®cient adenovirus vector was used for the in vivo transfer of MRP-1/CD9 cDNA. Intratumor injection of an adenovirus vector (rAd-MRP-1/CD9) expressing MRP-1/CD9 resulted in a 73.7% reduction in the number of pulmonary metastases of mice and the median survival time of mice treated with rAd-MRP-1/CD9 was signi®cantly longer than those treated with the rAd-b-gal vector (103.2+8.5 days vs 71.2+5.2 days, P50.001 respectively). These results support the expression of MRP-1/CD9 through gene transfer as a therapeutic strategy for preventing metastases and prolonging survival, and support the feasibility of gene transfer in a clinically relevant setting. Oncogene (2000) 19, 5221 ± 5226.
Introduction
The prevention of tumor metastasis is one of the most important problems in the design of therapies for patients with malignancies. The metastatic spread of a primary tumor to distant organs involves a series of predictable processes that include tumor cell detachment from the primary tumor, migration and invasion through the basement membranes of blood and lymph vessels, embolization, arrest and binding to vascular endothelium at secondary organs, extravasation, and invasion of the secondary organ. In these processes, cell motility is one of essential cellular functions which play an important role in tumor metastasis (Miyake and Hakomori, 1991) . In our previous studies we have established a murine monoclonal antibody (MAb), M31 ± 15, which inhibits cell motility by recognizing motility related protein-1 (MRP-1), a transmembrane glycoprotein . The amino acid sequence of MRP-1 is identical to that of CD9 reported in the same year (Boucheix et al., 1991) . Transfection with human MRP-1/CD9 cDNA revealed that cell motility was suppressed in the MRP-1/CD9-expressing cells (Ikeyama et al., 1993) . These observations suggested that MRP-1/CD9 might regulate cell motility, and that it could be a receptor for negative signal ligands. Recently, it has been reported by another laboratory that the MRP-1/CD9 gene was more highly expressed in the primary colon tumor as compared to its corresponding metastatic tumor using dierential display cloning (Cajot et al., 1997) . Based on these experimental results, we investigated whether the levels of MRP-1/CD9 expression in tumor tissues would be of value in predicting the clinical behavior of actual human tumors, and we found that in almost half of the cases, MRP-1/CD9 protein levels in the metastatic lymph nodes were lower than those in the respective primary breast cancers . Moreover, we revealed that reduced MRP-1/CD9 expression was associated with a poor prognosis in patients with breast cancers, non-small cell lung cancers (NSCLC) and pancreatic cancers (Miyake et al., 1996; Higashiyama et al., 1995; Sho et al., 1998) . In addition, other laboratories reported the same phenomenon in colon cancer and esophageal cancer (Mori et al., 1998; Uchida et al., 1999) . Thus, this gene suppresses tumor metastasis in various cancers, and its decreased expression may be involved in malignant progression. Similarly, several metastasis suppressor genes, maspin gene, mta-1 gene, nm23 gene and so on have been reported (Sheng et al., 1996; Toh et al., 1994; Barnes et al., 1991) . Especially, it has been reported that nm23 protein expression in breast cancer was associated with a good prognosis and absence of lymph node metastases, but that low nm23 mRNA levels correlated with the presence of lymph node metastases at surgery (Barnes et al., 1991) .
Recently, adenovirus vectors have been demonstrated to have the ability to transduce postmitotic cells and to have higher achievable titers (Curiel et al., 1996) . For example, the ability of the p53 gene to restore the normal growth properties to cancer cells has been studied extensively. In a recent clinical trial, patients with relapsed NSCLC with p53 mutations were treated with direct tumor injections of viruscontaining wild-type p53 and tumor regression was found in several patients (Roth et al., 1996) . On a theoretical basis, when MRP-1/CD9 is reintroduced into the appropriate cancer cells, there would be metastasis suppression of the tumors even in the absence of tumor resection. Thus, in the present study, we have considered recombinant adenovirus MRP-1/CD9 (rAd-MRP-1/CD9) delivery with direct intratumoral administration. Data from this model may support prophylactic prevention of pulmonary metastasis in patients with cancers by rAd-MRP-1/ CD9 gene therapy.
Results

Expression of MRP-1/CD9-transfected BL6 cells
Immunoblot analysis failed to demonstrate MRP-1/ CD9 protein in parental and b-gal-transduced BL6 cells, whereas rAd-MRP-1/CD9 transduced cells expressed high levels of MRP-1/CD9 protein (Figure 1 ). The major 25 KDa MRP-1/CD9 band was clearly evident in the Western blots of the soluble fraction of the rAd-MRP-1/CD9 transduced BL6 cells.
In vivo tumor growth
Initially, the optimum time point for injections was determined via intratumoral b-gal reporter gene and MRP-1/CD9 gene delivery, and assessment of expression time course (Figure 2a,b) . A peak average of 298+35 mU b-gal activity was observed at day 9, leveling o to 48+9 mU at day 15. On the other hand, a peak average of MRP-1/CD9 protein expression was found at day 6, and at day 15 no MRP-1/CD9 protein expression was detected. Thus, the interval time of intratumoral injection was determined to be 5 days. Transduction of BL6 cells by rAd-MRP-1/CD9 or control b-gal did not change the morphology or growth characteristics of these cells in vitro (data not shown). Moreover, there was no signi®cant dierence between rAd-MRP-1/CD9 transduced tumors and control rAd-b-gal tumors. The mean tumor volumes in the control b-gal vector and MRP-1/CD9-transduced group were 1431+359 and 1254.0+412 mm 3 , respectively, and the mean tumor weights were 1.56+0.39 and 1.35+0.45 g, respectively.
Immunohistochemical detection of MRP-1/CD9 in the tumor generated on the backs of Balb/c nude mice and pulmonary metastases
There was a striking dierence between tumors injected by rAd-b-gal and tumors by rAd-MRP-1/ CD9. As shown in Figure 3a 
Suppression of pulmonary metastases due to rAd-MRP-1/CD9
On 7 days after tumor inoculation, 1610 9 pfu of either rAd-b-gal or rAd-MRP-1/CD9 were injected into the approximately 3 mm in diameter tumor of the posterior foot pad of Balb/c nude mice. A total of 3610 9 pfu of rAds was inoculated into the foot pad tumors. For intratumor injections, 1610 9 pfu of either rAd-b-gal or rAd-MRP-1/CD9 were suspended in 100 ml of balanced salt solution and injected into the tumor using a 27-gauge needle mounted on a tuberculin syringe. On 5 days after the last injection, tumor-bearing feet were resected under ether anesthesia. Mice were killed 4 weeks after resection and the metastatic colonies in their lungs were counted. After tumor-bearing mice were sacri®ced, visible tumor nodules on the lung surface were counted to quantify tumor metastases (Figure 4 ). Consistent with qualitative observations, the number of lung tumors was reduced in mice that received rAd-MRP-1/CD9. Spontaneous metastasis from foot pad tumors was reduced with the average number of lung nodules being signi®cantly lower than in the controls (99+23 vs 26+17, P50.001).
rAd-MRP-1/CD9 effect on the survival of mice
For the purpose of evaluating the eect of rAd-MRP-1/CD9 on the survival of nude mice, rAd-b-gal (1610 9 pfu) or rAd-MRP-1/CD9 (1610 9 pfu) were stereotactically injected three times into the foot tumors before resection of the foot. As shown in Figure 5 , the median survival time of mice treated with rAd-MRP-1/ CD9 was signi®cantly longer than that of mice treated with the rAd-b-gal vector (103.2+8.5 days vs 71.2+5.2 days, P50.001 respectively). These data are consistent with the hypothesis that adenoviral-mediated transduction of the MRP-1/CD9 gene results in inhibition of tumor metastasis, without signi®cant eects on tumor cell proliferation.
Discussion
MRP-1/CD9 belongs to the transmembrane 4 superfamily (TM4SF), which has been functionally implicated in cell proliferation, activation and motility (Hemler et al., 1996) . Among TM4SF, MRP-1/CD9, KAI1/CD82 and ME491/CD63 are involved in metastasis suppression and their eects may be associated with integrin members Dong et al., 1995; Radford et al., 1995) . Especially, MRP-1/CD9 has been implicated in the invasion and metastasis of several categories of human tumors.
Recently it was reported that MRP-1/CD9 has an important role in sperm-egg fusion and muscle cell fusion (Miyado et al., 2000; Tachibana and Hemler, 1999) . However, the precise role of MRP-1/CD9 in limiting metastases remains unclear. Because the disruption of cell-to-cell contacts induces metastasis of tumor cells, it is of interest in the present context that anti-CD9 MAbs elicit an enhancement of Fcindependent heterotypic adhesion of pre-B cell lines to bone marrow stromal ®broblasts, but not to bone marrow stroma (Masellis-Smith and Shaw, 1994). Although we have no direct proof, on the basis of our previous experimental ®nding that the anti-MRP-1/CD9 MAb inhibits cell motility of various types of cancer cells Ikeyama et al., 1993) , we favor the hypothesis that MRP-1/CD9 aects motility and invasiveness by modulating the level of cellular adhesion. Higashiyama et al. reported that MRP-1/CD9 was reduced in metastatic tumors compared with levels in the corresponding primary lung tumors (Higashiyama et al., 1995) . Moreover, Cajot et al. reported that using dierential display cloning the MRP-1/CD9 gene was more highly expressed in the primary colon cancer than in its corresponding metastatic tumor (Cajot et al., 1997) . In addition, in the present study, we have shown that primary tumors transfected with human MRP-1/CD9 cDNA revealed a signi®cant reduction in metastases and no MRP-1/CD9 expression was found in their metastatic lesions of the lung. The present study extends these observations and supports the feasibility of gene transfer in a clinically relevant setting. For metastasis suppressor gene therapy, the use of a recombinant adenoviral vector system has many advantages. Unlike the low eciency of previously described retroviral systems (Culver et al., 1992; Old®eld et al., 1993) , adenoviral vectors have very high titers and eciency for direct delivery into cancer cells in vivo (Stratford-Perricaudet et al., 1990) . As a safety factor for the metastasis suppressor gene therapy strategy, the rapidly dividing tumor cells will be selectively targeted for adenoviral transduction over the surrounding normal tissues. The results show the extraordinary eciency of in situ transduction with adenovirus vectors since more than 90% of the melanoma cells expressed the transgene after intratumor gene transfer. Moreover, intratumor gene transfer had a demonstrable biologic eect resulting in signi®cant reduction in the number of pulmonary metastases. The failure of intratumor administered rAd-b-gal to aect lung metastasis development or host survival also argues against any nonspeci®c eects of the adenovirus vector. Results from intratumor gene transfer experiments suggest that this route oers a less traumatic and perhaps more ecient method for targeted gene therapy. Intratumor injection of rAd-MRP-1/CD9 resulted in signi®cant reductions in the incidence and severity of metastatic lung lesions. More importantly, hosts treated via intratumor gene transfer survived signi®cantly longer than control mice treated with b-gal vector. Although all of the control mice died of metastases within 90 days, all rAd-MRP-1/CD9-treated hosts were alive on day 90. Although injections were needed three times to produce optimal antimetastatic eects and the total virus dose was 3610 9 pfu, this adenoviral gene delivery provided a quick and simple method of producing MRP-1/CD9 expression in tumor cells both in vitro and in vivo. The success of this method should facilitate further development of delivery systems for cancer gene therapy. The predilection of rAd-MRP-1/CD9 to target the lung suggests that inoculation of patients before surgery or during other maneuvers that might exacerbate blood-borne shedding of tumor cells might, at the very least, serve as a prophylactic adjunct to conventional modalities. Considering that despite improved chemotherapeutic and radio-therapeutic procedures, no therapeutic modalities have been shown to be eective in preventing metastases or improving the 5-year survival rate of patients with distant metastasis, prevention of metastases using MRP-1/CD9 gene therapy might be one of the most important modalities.
Materials and methods
Cell lines and animals
The mouse melanoma BL6 cells (Riken Gene Bank, Tsukuba, Japan) were maintained in RPMI1640 containing 10% FCS. Eight-week-old male Balb/c nude mice were purchased from Nippon Clea (Sizuoka, Japan). The 293 cell line, a permanent line of primary human embryonic kidney transformed by sheared adenovirus DNA, was purchased from Takara Biomedicals (Otsu, Japan).
Recombinant adenoviruses
An E1-deleted replication-de®cient recombinant adenovirus encoding human MRP-1/CD9 (rAd-MRP-1/CD9) under the control of the human CMV immediate early promoter was performed using an Adenovirus Expression Vector kit (Takara Biomedicals, Otsu, Japan) and following the manufacturer's protocol. E1-deleted control adenoviruses were constructed containing the bacterial lacZ gene (rAd-bgal) under the control of the human CMV gene promoter (Stratford-Perricaudet et al., 1992) . Adenovirus production was carried out using a 293 human embryonic kidney cell line which provided the E1 protein in trans. CsCl-puri®ed recombinant human adenoviruses were stored in a PBS solution containing 3% sucrose, and 2 mM MgCl 2 . Infectious titers measured in plaque forming units (pfu/ml) in adenovirus stocks or serum samples were determined by a limiting dilution bioassay using the 293 cell line (Chen et al., 1995) , and testing for replication competent adenovirus was subsequently performed.
Detection of transgene expression in vitro
b-galactosidase expression was assayed by plating cells in 24-well plates (Costar Corp., Cambridge, MA, USA) at 1610 5 cells/well. After overnight incubation, infections with rAd-bgal were performed at a multiplicity of infection (MOI) of 30 pfu per cell in a volume of 1 ml. After 2 days, cells were ®xed with 3.7% formaldehyde/PBS, washed, and stained overnight with 1 mg/ml X-gal solution containing 10% DMF, 1.2 mM MgCl 2 , 3 mM K 3 FeCN, and 3 mM K 4 FeCN in PBS (Harris et al., 1996) .
Detection of cellular MRP-1/CD9 protein was accomplished by Western blot of untreated cells or cells 2 days after treatment with rAd-MRP-1/CD9 or control rAd-b-gal. Cells were lysed with 1% CHAPS. An aliquot of the soluble fraction was subjected to slab gel electrophoresis, followed by Western blotting and probing with anti-MRP-1/CD9 MAb (M31-15), and horseradish peroxidase-conjugated goat antimouse IgG antibody (Chemicon, Temecula, CA, USA) (Kondo et al., 1998) . The membrane was then reacted with enhanced chemiluminescence detection reagent (Amersham, Backinghamshire, UK) and exposed to X-ray ®lm at room temperature. The total protein content applied to each lane was adjusted to identical concentrations. Cells of the human breast cancer cell line ZR-75-30 were used as positive controls. Band intensity was evaluated by densitometry.
Assessment of long-term adenovirus persistence and MRP-1/CD9 expression in established tumors
Melanomas generated on the backs of Balb/c nude mice by s.c. injection of 5610 5 BL6 cells, were injected 10 days later with a single infusion of 1610 9 pfu of either rAd-b-gal or rAd-MRP-1/CD9 in a total volume of 100 ml virus dialysis buer. Intra-tumoral injection was performed slowly with a 27-gauge needle to minimize leakage. At 3, 6, 9, 12 and 15 days after either rAd-b-gal or rAd-MRP-1/CD9 treatment, the mice were sacri®ced (n=5, respectively). Each tumor was powdered under liquid nitrogen, resuspended in 0.25 M TrisHCl, pH 7.8, with three subsequent thaw-freeze cycles, and bgal enzyme activity was measured by a chemiluminescence assay (Galacto-Light, Tropix, Bedford, MA, USA) (Bonnekoh et al., 1998) . b-gal activities (mU) were calculated for each tumor with respect to the total volume of lysate prepared from a given tumor, and background b-gal activity from untreated tumor tissue (46+29 mU n=5) was subtracted. In contrast, MRP-1/CD9 protein in tumor tissues was detected by Western blot as described above. To classify the specimens on the basis of Western blotting, the 25 kDa band obtained with the positive control cells ZR-75-30 was set at 100%. In addition, to evaluate growth characteristics of MRP-1/CD9-transduced BL6 cells in vivo, mice were sacri®ced 15 days after the intra-tumoral injection of control vector or rAd-MRP-1/CD9 (1610 9 pfu), and tumor size was assessed.
Immunohistochemical assays
As the MRP-1/CD9 antigen is not preserved in formalin-®xed paran-embedded tissues, we used frozen sections for these assays; they were performed as previously described . Brie¯y, the sections were immersed for 30 min in 0.3% H 2 O 2 (in absolute methanol) to inhibit endogenous peroxidase activity, and then treated with 5% bovine serum albumin. Sections were incubated for 2 h with the anti-MRP-1/CD9 MAb M31-15, sequentially followed by incubation with biotinylated horse anti-mouse IgG and the avidin-biotinperoxidase complex. Antibody binding was visualized with 3,3'-diaminobenzidine tetrahydrochloride in the presence of 0.05% H 2 O 2 . The sections were then counterstained with hematoxylin, dehydrated and mounted. Biotinylated horse anti-mouse IgG, avidin and biotin were purchased from Vector Laboratories, Inc. (Burlingame, CA, USA). Sections incubated with mouse myeloma SP 2 supernatant served as negative reaction controls.
MRP-1/CD9 gene therapy
To assess the spontaneous metastasis, 5610 5 cells were inoculated into the posterior foot pad of male Balb/c nude mice (n=7, respectively). After 7 days, 1610 9 pfu of either rAd-b-gal or rAd-MRP-1/CD9 were injected into the tumor of the posterior foot pad of Balb/c nude mice at three time points on day 7, 12 and 17 after tumor inoculation. A total of 3610 9 pfu of rAds was inoculated into the foot pad tumors. For intratumor injections, 1610 9 pfu of either rAdb-gal or rAd-MRP-1/CD9 were suspended in 100 ml of balanced salt solution and injected into the tumor using a 27-gauge needle mounted on a tuberculin syringe. On 5 days after the last injection, tumor-bearing feet were resected under ether anesthesia. Mice were killed 4 weeks after resection and the metastatic colonies in their lungs were counted. Moreover, the same experiment was performed to observe the eects of rAd-b-gal and rAd-MRP-1/CD9 on the survival of mice (n=7, respectively). There were no signs of cachexia during this period, and all animals appeared clinically healthy at the time of the adenovirus injection.
Statistical analysis
Dichotomous variables were analysed with Pearson's chisquare test. Mann-Whitney's U test was used to compare interval variables. The survival was de®ned as the period from the date of resection to the date of death. The KaplanMeier method was used to estimate the probability of overall survival as a function of time (Kaplan and Meier, 1958) , and dierences in the survival of subgroups were compared with Mantel's log-rank test (Mantel, 1966) . All P values were based on two-tailed statistical analyses, and a P value 50.05 was considered to indicate statistical signi®cance.
Abbreviations
MAb, monoclonal antibody; rAd, recombinant adenovirus; b-gal, b-galactosidase; CD, white cell dierentiation antigen.
